Astrana Health guides 2026 revenue up ~24% and adjusted EBITDA up 29%

 

Astrana Health beats Q4 2025 estimates with non-GAAP EPS $0.12 (+180% YoY) and revenue $950.5M (+43% YoY), guides 2026 revenue up ~24% and adjusted EBITDA up 29%

• Company will file Form 12b-25 for material weakness in internal controls over acquisition and purchase accounting processes.
• Company's board of directors increased share repurchase authorization to $100 million.

https://finviz.com/quote.ashx?t=ASTH&p=d